{
    "clinical_study": {
        "@rank": "43627", 
        "arm_group": [
            {
                "arm_group_label": "1 Cyclosporine + Faldaprevir", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2 Tacrolimus + Faldaprevir", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to investigate the effect of multiple-dose\n      faldaprevir (FDV) on the single-dose pharmacokinetics of cyclosporine or tacrolimus"
        }, 
        "brief_title": "Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy males or females subjects\n\n          -  Age 18 to 50 years (incl.)\n\n          -  Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.)\n\n          -  Signed and dated written informed consent prior to admission to the study\n\n        Exclusion criteria:\n\n          -  Any finding in the medical examination (including blood pressure, pulse rate or ECG)\n             deviating from normal and judged clinically relevant by the investigator.\n\n          -  Systolic blood pressure (BP) less than 100 mmHg and more than 140 mmHg.\n\n          -  Diastolic BP less than 60 mmHg and more than 90 mmHg.\n\n          -  Pulse rate (PR)  less than 50 bpm and more than 90 bpm.\n\n          -  Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          -  Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          -  Positive QuantiFERON-TB Gold In-Tube"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016625", 
            "org_study_id": "1241.61", 
            "secondary_id": "2013-003435-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 Cyclosporine + Faldaprevir", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 Tacrolimus + Faldaprevir", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1 Cyclosporine + Faldaprevir", 
                "intervention_name": "Cyclosporine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 Tacrolimus + Faldaprevir", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Immunosuppressive Agents", 
                "Tacrolimus"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mannheim", 
                    "country": "Germany"
                }, 
                "name": "1241.61.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation of Potential Drug-drug Interactions Between Faldaprevir and Immunosuppressants (Cyclosporine and Tacrolimus) in Healthy Male and Female Subjects (Open-label, Fixed-sequence Trial)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }, 
            {
                "measure": "C24,ss (maximum measured concentration of the analyte in plasma at steady state over a 24 hour dosing interval)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016625"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}